Evidence map›Paper›PMID 37934757›Full record

ArticlePLoS pathogens2023

KSHV vIL-6 enhances inflammatory responses by epigenetic reprogramming.

Tomoki Inagaki, Kang-Hsin Wang, Ashish Kumar, Chie Izumiya, Hiroki Miura, Somayeh Komaki, Ryan R Davis, Clifford G Tepper, Harutaka Katano, Michiko Shimoda and 1 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Viral oncogenesis in cancer: from mechanisms to therapeutics.Signal transduction and targeted therapy · 2025
    Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Tomoki InagakiDepartment of Dermatology, School of Medicine, the University of California Davis (UC Davis), Sacramento, California, United States of America.ORCID 0009-0007-2332-9895
Kang-Hsin WangDepartment of Dermatology, School of Medicine, the University of California Davis (UC Davis), Sacramento, California, United States of America.
Ashish KumarDepartment of Dermatology, School of Medicine, the University of California Davis (UC Davis), Sacramento, California, United States of America.
Chie IzumiyaDepartment of Dermatology, School of Medicine, the University of California Davis (UC Davis), Sacramento, California, United States of America.
Hiroki MiuraDepartment of Dermatology, School of Medicine, the University of California Davis (UC Davis), Sacramento, California, United States of America.
Somayeh KomakiDepartment of Dermatology, School of Medicine, the University of California Davis (UC Davis), Sacramento, California, United States of America.
Ryan R DavisDepartment of Pathology and Laboratory Medicine, School of Medicine, UC Davis, Sacramento, California, United States of America.
Clifford G TepperDepartment of Biochemistry and Molecular Medicine, School of Medicine, UC Davis, Sacramento, California, United States of America.
Harutaka KatanoDepartment of Pathology, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan.
Michiko ShimodaDepartment of Dermatology, School of Medicine, the University of California Davis (UC Davis), Sacramento, California, United States of America.
Yoshihiro IzumiyaDepartment of Dermatology, School of Medicine, the University of California Davis (UC Davis), Sacramento, California, United States of America.ORCID 0000-0002-9184-2603
University of California, Davis · USNational Institute of Infectious Diseases · JP

Funding

Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI KC KENT LLOYD · 2002 to 2026
$84.9M
Nano-Therapeutic Approaches for Oncogenic Herpesvirus-Mediated MalignanciesR01CA232845 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI IZUMIYA, YOSHIHIRO, LI, YUANPEI · 2018 to 2022
$3.2M
Studies on Epigenetically Active Latent Chromatin MaintenanceR01AI167663 · NIAID · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Yoshihiro Izumiya · 2022 to 2026
$2.6M
Spatiotemporal Gene Regulation and KSHV ReplicationR01CA225266 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI IZUMIYA, YOSHIHIRO · 2018 to 2022
$1.8M
Development of Precision Analyses to Reveal "Hit&Run" EffectsR21AI155515 · NIAID · UNIVERSITY OF CALIFORNIA AT DAVIS · PI IZUMIYA, YOSHIHIRO · 2021 to 2022
$432k
NCI NIH HHS P30 CA093373NCI NIH HHS R01 CA225266NCI NIH HHS R01 CA232845NIAID NIH HHS R01 AI167663NIAID NIH HHS R21 AI155515
6 · The paper itself

Abstract

Kaposi sarcoma-associated herpesvirus (KSHV) inflammatory cytokine syndrome (KICS) is a newly described chronic inflammatory disease condition caused by KSHV infection and is characterized by high KSHV viral load and sustained elevations of serum KSHV-encoded IL-6 (vIL-6) and human IL-6 (hIL-6). KICS has significant immortality and greater risks of other complications, including malignancies. Although prolonged inflammatory vIL-6 exposure by persistent KSHV infection is expected to have key roles in subsequent disease development, the biological effects of prolonged vIL-6 exposure remain elusive. Using thiol(SH)-linked alkylation for the metabolic (SLAM) sequencing and Cleavage Under Target & Release Using Nuclease analysis (CUT&RUN), we studied the effect of prolonged vIL-6 exposure in chromatin landscape and resulting cytokine production. The studies showed that prolonged vIL-6 exposure increased Bromodomain containing 4 (BRD4) and histone H3 lysine 27 acetylation co-occupancies on chromatin, and the recruitment sites were frequently co-localized with poised RNA polymerase II with associated enzymes. Increased BRD4 recruitment on promoters was associated with increased and prolonged NF-κB p65 binding after the lipopolysaccharide stimulation. The p65 binding resulted in quicker and sustained transcription bursts from the promoters; this mechanism increased total amounts of hIL-6 and IL-10 in tissue culture. Pretreatment with the BRD4 inhibitors, OTX015 and MZ1, eliminated the enhanced inflammatory cytokine production. These findings suggest that persistent vIL-6 exposure may establish a chromatin landscape favorable for the reactivation of inflammatory responses in monocytes. This epigenetic memory may explain the greater risk of chronic inflammatory disease development in KSHV-infected individuals.

Indexed as

Herpesviridae InfectionsHerpesvirus 8, HumanSarcoma, KaposiBromodomain Containing ProteinsCell Cycle ProteinsChromatinCytokinesEpigenesis, GeneticHumansInterleukin-6Nuclear ProteinsTranscription FactorsBRD4 protein, humanBromodomain Containing ProteinsCell Cycle ProteinsChromatinCytokinesInterleukin-6Nuclear ProteinsTranscription Factors

Identifiers

PMID37934757
PMCPMC10656005
OpenAlexW4388451985

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.